C-Path's New Paper in Nature Reviews Drug Discovery Highlights How to Maximize the Regulatory Impact of Consortium-Based Projects
BRUSSELS and AMSTERDAM, June 16, 2025 /PRNewswire/ — The Innovative Health Initiative (IHI) and Critical Path Institute® (C-Path) today announced the publication of a peer-reviewed paper in Nature Reviews Drug Discovery, highlighting insights from multistakeholder global consortia launched over the past two decades to address barriers in drug development. Titled 'Delivering regulatory impact from consortium-based projects,' the paper presents a joint approach to addressing key challenges in developing tools to support regulatory decision-making.
Drawing on the experience of cross-sector partnerships, the authors stress that collaboration alone is not enough to achieve meaningful impact on accelerating drug development. Key aspects to maximize regulatory impact include early regulatory engagement, clear evidentiary standards, and long-term planning for data access and sustainability.
'This work emphasizes the urgency—and feasibility—of building globally coordinated, cross-sector efforts to drive innovation for patients who have long been underserved,' said C-Path Vice President of Global Affairs Cécile Ollivier. 'By aligning stakeholders and lowering technical and regulatory barriers, we can reshape the drug development landscape.'
As regulatory science becomes more central to translating innovation into patient benefit, the authors highlight the importance of taking a structured, strategic approach to regulatory issues, starting from the earliest stages of project planning and running right through to the post-project stage.
'We are collectively working to turn exciting advances in health research and innovation into real benefits for people and patients,' said Nathalie Seigneuret, Senior Scientific Project Manager at IHI. 'Regulatory science is key to making this happen, and we hope that this paper will help projects deliver results that meet regulators' needs.'
Aligned with the IHI guide for applicants and project consortia on regulatory considerations for IMI and IHI projects, the paper outlines priorities for implementation:
A clear regulatory strategy defined at project start
A tailored data management plan aligned with regulatory goals
A sustainability plan to ensure post-project data availability
Early engagement with regulators led by experienced collaborators
This paper reflects growing momentum for innovative and sustainable research whose results strive to accelerate medical product development and inform regulatory decision-making.
Read the full paper, here, and supplementary material, here.
About IHI
The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management.
IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. IHI's total budget is EUR 2.4 billion. Half of this comes from Horizon Europe, the EU's research and innovation programme. The IHI industry partners have committed EUR 1 billion to IHI, and a further EUR 200 million can be committed by other organisations that decide to become Contributing Partners.
IHI builds on the successes of the Innovative Medicines Initiative (IMI), and the IHI Programme Office continues to manage the IMI project portfolio. For more information visit ihi.europa.eu and follow IHI on LinkedIn, Bluesky and Mastodon.
About Critical Path Institute
Founded in 2005, as a public-private partnership in response to the FDA's Critical Path Initiative, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org and follow C-Path on LinkedIn, X, Facebook, Instagram, BlueSky and YouTube.
Media Contacts:
Catherine BrettExternal Relations ManagerCatherine.brett@ihi.europa.eu+32 2 541 8214
Roxan Triolo OlivasC-Path Communicationsrolivas@c-path.org+1 520-954-1634
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
4 days ago
- Malaysian Reserve
C-Path's New Paper in Nature Reviews Drug Discovery Highlights How to Maximize the Regulatory Impact of Consortium-Based Projects
BRUSSELS and AMSTERDAM, June 16, 2025 /PRNewswire/ — The Innovative Health Initiative (IHI) and Critical Path Institute® (C-Path) today announced the publication of a peer-reviewed paper in Nature Reviews Drug Discovery, highlighting insights from multistakeholder global consortia launched over the past two decades to address barriers in drug development. Titled 'Delivering regulatory impact from consortium-based projects,' the paper presents a joint approach to addressing key challenges in developing tools to support regulatory decision-making. Drawing on the experience of cross-sector partnerships, the authors stress that collaboration alone is not enough to achieve meaningful impact on accelerating drug development. Key aspects to maximize regulatory impact include early regulatory engagement, clear evidentiary standards, and long-term planning for data access and sustainability. 'This work emphasizes the urgency—and feasibility—of building globally coordinated, cross-sector efforts to drive innovation for patients who have long been underserved,' said C-Path Vice President of Global Affairs Cécile Ollivier. 'By aligning stakeholders and lowering technical and regulatory barriers, we can reshape the drug development landscape.' As regulatory science becomes more central to translating innovation into patient benefit, the authors highlight the importance of taking a structured, strategic approach to regulatory issues, starting from the earliest stages of project planning and running right through to the post-project stage. 'We are collectively working to turn exciting advances in health research and innovation into real benefits for people and patients,' said Nathalie Seigneuret, Senior Scientific Project Manager at IHI. 'Regulatory science is key to making this happen, and we hope that this paper will help projects deliver results that meet regulators' needs.' Aligned with the IHI guide for applicants and project consortia on regulatory considerations for IMI and IHI projects, the paper outlines priorities for implementation: A clear regulatory strategy defined at project start A tailored data management plan aligned with regulatory goals A sustainability plan to ensure post-project data availability Early engagement with regulators led by experienced collaborators This paper reflects growing momentum for innovative and sustainable research whose results strive to accelerate medical product development and inform regulatory decision-making. Read the full paper, here, and supplementary material, here. About IHI The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management. IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. IHI's total budget is EUR 2.4 billion. Half of this comes from Horizon Europe, the EU's research and innovation programme. The IHI industry partners have committed EUR 1 billion to IHI, and a further EUR 200 million can be committed by other organisations that decide to become Contributing Partners. IHI builds on the successes of the Innovative Medicines Initiative (IMI), and the IHI Programme Office continues to manage the IMI project portfolio. For more information visit and follow IHI on LinkedIn, Bluesky and Mastodon. About Critical Path Institute Founded in 2005, as a public-private partnership in response to the FDA's Critical Path Initiative, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit and follow C-Path on LinkedIn, X, Facebook, Instagram, BlueSky and YouTube. Media Contacts: Catherine BrettExternal Relations 2 541 8214 Roxan Triolo OlivasC-Path Communicationsrolivas@ 520-954-1634
The Star
01-06-2025
- The Star
Selangor schools to rep Malaysia in regional challenge
TWO schools in Selangor will represent Malaysia at the upcoming AIA Healthiest Schools (AHS) Regional Awards in Da Nang, Vietnam, where they will compete with winners from other nations for prizes totalling US$100,000 (RM424,500). SJK (C) Hwa Lien and SMK Saujana Utama, the national-level primary and secondary champions, will compete alongside winning schools from Indonesia, Thailand, Hong Kong, Australia, Vietnam, Sri Lanka and the Philippines in the regional round of the competition next month. During the AHS Awards ceremony at a hotel in Kuala Lumpur on May 22, SJK (C) Hwa Lien and SMK Saujana Utama received US$10,000 (RM42,450) each for coming out on top in their respective categories of the AHS national-level competition. The awards ceremony celebrated the achievements of 18 primary and secondary schools, recognising their innovative and impactful efforts in promoting student well-being and driving meaningful change within school communities. The winning schools were selected based on project scope and execution, level of engagement with teachers, students and the wider community, overall impact as well as long-term sustainability. At this year's ceremony, which marked the culmination of the second edition of the AHS Competition – a key highlight of the AHS programme – primary and secondary schools received prize money totalling US$100,000 (RM424,500). Held from October last year to March this year, the competition received over 60 entries from government, private and international schools across Malaysia. SJK (C) Hwa Lien, a small island school located on Pulau Ketam, was awarded the top prize for its My School, My Home 2.0 initiative. Congratulations: (Left) Chee and Education Ministry daily school management division senior deputy director Abidin Marjan (sixth and seventh from right) presenting the award to SMK Saujana Utama principal Noor Hayati Embong (centre), project coordinator Hamidah Mukhtar (far right) and teachers. (Right) Nine primary schools were honoured for promoting health and well-being. Designed to address mental health challenges stemming from digital stress, social isolation and language barriers among students, the school introduced inclusive modules focusing on emotional well-being, cultural celebration, physical activity, and language support. The initiative successfully fostered a more connected and resilient student body with the support of parents, the Orang Asli community and neighbouring schools. The second, third and fourth place winners in the primary school category were SK Jalan Empat in Selangor, and SK Oran and SK Kuala Perlis in Perlis, respectively. SJK (C) Pui Ying in Selangor, SK Padang Temu in Melaka, SJK (C) Lawan Kuda Baru in Perak, SJK (C) Han Chiang in Penang and SK Changkat Jawi in Perlis received the Highly Commended Award. In the secondary school category, SMK Saujana Utama in Sungai Buloh clinched first place for Canscape, a creative art-therapy programme under its Terapi Seni Ekspresi mental health initiative, which saw students using recycled tin cans as canvases to express their emotions, turning a simple and low-cost artistic outlet into a powerful tool for emotional regulation. The initiative helped reduce stress and negative behaviours such as vandalism while promoting emotional awareness and empathy. SMK Kuala Jenderis and SMK Kampung Baru Kerteh in Terengganu, and SMK Bukit Baru in Melaka came in second, third and fourth place, respectively, in the secondary school category. SMK (P) Treacher Methodist in Perak, SMK Telok Gadong in Selangor, Sayfol International School in Kuala Lumpur, SMK Paya Rumput in Melaka and SMK Kijal in Terengganu were all presented with the Highly Commended Award. Each of the second, third and fourth prize winners in both the primary and secondary school categories took home US$7,500 (RM31,838), while recipients of the Highly Commended Award received a cash prize of US$3,500 (RM14,858) each. AIA Malaysia chief marketing officer Chee Foong Wai said the AHS programme is part of the company's aim to nurture a culture of health and well-being from an early age. 'We believe real change can start in the classroom. In just two years, what began as a simple vision has made progressive strides. The programme has sparked creativity and passion and empowered the next generation to take charge of their physical, mental and environmental well-being. 'We're incredibly encouraged by the response to this year's competition, which saw twice as many entries compared to last year. It's a positive sign that the momentum is growing – with more schools taking proactive steps to create healthier and happier learning environments for their students,' she said during the awards ceremony. Thanking its partners, she said AIA was proud to celebrate the remarkable efforts of children and educators who are driving real change and making a difference in their schools. Endorsed by the Education Ministry, the AHS programme, launched in 2023, is designed to empower schools to promote healthy eating, active lifestyles, mental well-being and sustainability among students aged five to 16. The programme provides free multilingual teaching resources in English, Bahasa Malaysia and Mandarin, as well as hands-on teacher workshops to equip teachers to effectively introduce health and well-being concepts in the classrooms. Schools interested in registering for the AHS programme can find more information at where teaching resources are also available. Entries for the third edition of the AHS competition can be submitted from October this year.
Malaysian Reserve
21-05-2025
- Malaysian Reserve
The 10,000 Brains Project Launches the "Path-ND" Digital Brain Banking Program to Transform Neurodegenerative Disease Research
Funding from the Kissick Family Foundation Expands Frontotemporal Dementia Data; New Partnership with The Michael J. Fox Foundation Enhances Parkinson's Research OAKLAND, Calif., May 20, 2025 /PRNewswire/ — The 10,000 Brains Project today announced the launch of Path-ND, a groundbreaking digital brain banking program designed to digitize at least 5,000 neuropathology cases over the next two years. This major initiative will make ultra high-resolution brain tissue images more widely accessible for neurodegenerative disease research and on an unprecedented scale, enabling researchers to unlock critical insights into diseases like Alzheimer's disease, Parkinson's disease, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS). Unlike traditional approaches that study these disorders in isolation, The 10,000 Brains Project is leading the new era in neuroscience research, focused on connecting discoveries across the full spectrum of neurodegenerative disorders using recent breakthroughs in computer science. Path-ND is a critical step in moving the field forward. It embraces the complexity of these diseases and aims to rethink how we define, diagnose, and treat them. By breaking down silos and enabling large-scale comparative research, Path-ND seeks to catalyze the kinds of breakthroughs that have remained out of reach for too long. 'Path-ND is about more than digitizing brain tissue slides—it's about transforming the entire approach to neurodegenerative research,' said Patrick Brannelly, CEO of The 10,000 Brains Project. 'Just as tumor biopsies have revolutionized cancer treatment, we believe digitized brain tissue will enable researchers to take a new approach and crack the code of neurodegenerative disease.' With $3 million in funding from the Kissick Family Foundation, the program will create the world's largest FTD dataset, an area of urgent need due to the disease's highly variable symptoms and complex pathology. Additionally, a new partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF) will fund additional digitization of brain tissue from additional patients with Parkinson's disease and related disorders. Leading this initiative is Mukta Phatak, PhD, a highly accomplished bioinformatics expert with more than 15 years of experience integrating technology with scientific research. Dr. Phatak comes to The 10,000 Brains Project from Gates Ventures, where she served in a technical leadership role on the Alzheimer's Disease Data Initiative. Introducing Path-ND: A Next Generation Research Platform For decades, researchers studying neurodegenerative diseases have faced a fundamental challenge: the examination of human brain tissue provides ground truth, but access to high-quality, well-characterized samples has been severely limited. These limitations have slowed progress in understanding the full biological complexity of neurodegenerative conditions. Path-ND offers a powerful solution. By enabling more researchers to examine brain tissue directly, it opens the door to identifying new mechanisms and previously unrecognized disease subtypes. Analyzing this data with artificial intelligence (AI) and other advanced data science techniques could fundamentally reshape our understanding of neurodegeneration—revealing that these diseases may be both more biologically diverse and more interconnected than we ever imagined. It enables the possibility of rethinking traditional diagnostic categories and creates opportunities to uncover novel therapeutic targets. Path-ND will be the foundation for this change: a groundbreaking digital brain banking platform that aims to centralize and democratize access to neuropathology data. Built on the secure, cloud-based Verily Workbench, Path-ND will allow talented researchers from across the globe to explore high-resolution digital images of brain tissue without the constraints of geography. Path-ND is designed with interoperability at its core, ensuring that the data will also be made accessible through other biomedical research platforms. This will create a truly connected ecosystem where open data sharing, large-scale analytics, and AI-driven discovery can thrive. By doing so, Path-ND will not only accelerate research but also drive a new era of cross-disease insight, reshaping the future of neurodegenerative disease science. Advancing Research Through Collaboration Through generous funding from the Kissick Family Foundation, Path-ND will expand its datasets to include FTD cases—a disease that remains among the most devastating and least understood. Unlike Alzheimer's, which primarily affects memory, FTD strikes at the core of personality, behavior, and language, robbing individuals of their ability to communicate, connect, and function in daily life. It is the most common cause of dementia in people under 60, yet it remains one of the least understood neurodegenerative disorders, with no cure and limited treatment options. This investment is about expanding hope for FTD patients and families who desperately need answers. 'As advocates and funders, we see an urgent need for creative new approaches in neurodegeneration research,' said Kasey Kissick of the Kissick Family Foundation. 'The Path-ND program is an important step in the transition to a more agile and productive research ecosystem. We are proud to support this effort.' In addition, a new collaboration with The Michael J. Fox Foundation will be a major catalyst for Parkinson's disease and related disorders, integrating its newly generated digital brain inventory into the Path-ND Data Hub. Parkinson's is the fastest-growing neurodegenerative disease, affecting millions worldwide, yet there are still no definitive biomarkers and no way to stop its relentless progression. By incorporating MJFF's digital brain inventory, Path-ND is expanding access to valuable data, enabling more cross-disease comparisons, and capturing significant cost savings through shared infrastructure. 'Finding new ways to provide researchers with the tools they need to accelerate Parkinson's research is a key priority for The Michael J. Fox Foundation,' said Leslie Kirsch, vice president, head of research data resources at MJFF. 'This collaboration with The 10,000 Brains Project expands access to high-resolution brain tissue, supporting the broader scientific community in uncovering insights into Parkinson's disease and related disorders.' Mukta Phatak joins The 10,000 Brains Project to Lead Path-ND The 10,000 Brains Project has appointed Mukta Phatak, PhD, a seasoned leader in data science and bioinformatics, to lead Path-ND. Dr. Phatak is an accomplished expert in biomedical innovation and data science. She earned her PhD in bioinformatics from the University of Cincinnati and has over 15 years of experience in data strategy, AI/ML model development, and scientific technology integration across academia, industry, and the nonprofit sector. Most recently, she served as Director of Data Science for the Alzheimer's Disease Data Initiative, which is part of the Health and Life Sciences Division at Gates Ventures. During her time at Gates Ventures, Dr. Phatak played a pivotal role in designing data architectures, enhancing customer engagement, and leveraging advanced analytics to drive progress in Alzheimer's research. 'Digitizing brain pathology is the next frontier in precision neuroscience,' said Dr. Phatak. 'With Path-ND, we're building an open, scalable, and interoperable resource that will unlock discovery at a whole new level. Path-ND will bring us closer to truly personalized care for patients everywhere.' A Call to Action: Expanding the Future of Digital Brain Research The 10,000 Brains Project invites researchers, institutions, and biobanks to contribute additional neuropathology datasets to expand the scope and impact of Path-ND. By increasing the diversity and scale of digitized brain tissue data, this initiative will unlock insights that no single dataset could reveal alone. Forward-thinking philanthropic partners and investors are also encouraged to join the movement. Expanding Path-ND's reach will allow the project to include more rare diseases, enhance AI capabilities, support more researchers, and accelerate the pace of discovery. If you are a researcher interested in contributing data or a funder looking to make a lasting impact, visit to learn more. About The 10,000 Brains Project The 10,000 Brains Project is a nonprofit initiative that is leading the new era in neuroscience. We are dedicated to driving positive change for the millions of people affected by neurodegenerative diseases worldwide. By working across neurodegenerative diseases and harnessing the full potential of innovative tools and technologies, we aim to accelerate breakthroughs in earlier detection, better treatments, and more personalized care. To learn more about our priorities, programs, and partnerships, visit: About The Kissick Family Foundation The Kissick Family Foundation aims to catalyze change through bold and dynamic philanthropy. They provide critical early support for the leaders, researchers, and entrepreneurs who are finding cures, repairing catastrophic damage to the planet, and changing entire fields of study. The foundation invests in cutting-edge scientific research and awareness building for neurodegenerative diseases, with a focus on frontotemporal dementia. They are equally committed to backing transformative ideas in the climate space, specifically ocean-based solutions with the potential to mitigate and reverse harm to the planet. For more information, visit Media Contact: Chantelle Ferland-Beckham, PhD chantelle@ Consulting, LLC
